IL113210A - 1H-Indole - 3 gliaxylamide sPLA2 inhibitors and preparations of pharmaceutical compounds containing them - Google Patents

1H-Indole - 3 gliaxylamide sPLA2 inhibitors and preparations of pharmaceutical compounds containing them

Info

Publication number
IL113210A
IL113210A IL11321095A IL11321095A IL113210A IL 113210 A IL113210 A IL 113210A IL 11321095 A IL11321095 A IL 11321095A IL 11321095 A IL11321095 A IL 11321095A IL 113210 A IL113210 A IL 113210A
Authority
IL
Israel
Prior art keywords
group
methyl
indol
amino
alkyl
Prior art date
Application number
IL11321095A
Other languages
English (en)
Hebrew (he)
Other versions
IL113210A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL113210A0 publication Critical patent/IL113210A0/xx
Publication of IL113210A publication Critical patent/IL113210A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL11321095A 1994-04-01 1995-03-31 1H-Indole - 3 gliaxylamide sPLA2 inhibitors and preparations of pharmaceutical compounds containing them IL113210A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22191694A 1994-04-01 1994-04-01

Publications (2)

Publication Number Publication Date
IL113210A0 IL113210A0 (en) 1995-06-29
IL113210A true IL113210A (en) 2001-01-28

Family

ID=22829963

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11321095A IL113210A (en) 1994-04-01 1995-03-31 1H-Indole - 3 gliaxylamide sPLA2 inhibitors and preparations of pharmaceutical compounds containing them

Country Status (29)

Country Link
US (6) US5654326A (sv)
EP (5) EP1950200B1 (sv)
JP (1) JP3109974B2 (sv)
KR (1) KR100368707B1 (sv)
CN (1) CN1067054C (sv)
AT (2) ATE220394T1 (sv)
AU (1) AU688458B2 (sv)
BR (1) BR9501404A (sv)
CA (1) CA2146097C (sv)
CO (1) CO4370099A1 (sv)
CZ (1) CZ82295A3 (sv)
DE (1) DE69527322T2 (sv)
DK (2) DK1950200T3 (sv)
ES (2) ES2377223T3 (sv)
FI (1) FI114793B (sv)
HU (1) HUT72048A (sv)
IL (1) IL113210A (sv)
MX (1) MX9501608A (sv)
MY (1) MY112897A (sv)
NO (1) NO304186B1 (sv)
NZ (1) NZ270848A (sv)
PE (1) PE18696A1 (sv)
PL (1) PL180523B1 (sv)
PT (1) PT675110E (sv)
RU (1) RU2128169C1 (sv)
SI (1) SI0675110T1 (sv)
TW (1) TW383302B (sv)
UA (1) UA47387C2 (sv)
ZA (1) ZA952693B (sv)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL180523B1 (pl) * 1994-04-01 2001-02-28 Eli Lilly & Co Nowy zwiazek, pochodna 1H-indolo-3-glioksylamidu i srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
JPH08193074A (ja) * 1994-11-18 1996-07-30 Nippon Bayeragrochem Kk 除草性1−シクロプロピルテトラゾリノン類
CN1092639C (zh) * 1995-01-06 2002-10-16 东丽株式会社 苯稠合杂环衍生物及其用途
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
CA2279211A1 (en) * 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
US5972988A (en) * 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) * 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
JP2001513555A (ja) * 1997-08-28 2001-09-04 イーライ・リリー・アンド・カンパニー 非リウマチ様関節炎の処置方法
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
DE69830335T2 (de) 1997-10-27 2006-02-02 Eli Lilly And Co., Indianapolis MORPHOLINO-N-ETHYL ESTER PRODROGEN VON INDOL sPLA 2 HEMMER
WO1999021545A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
EP1039901A1 (en) * 1997-11-14 2000-10-04 Eli Lilly And Company Treatment for alzheimer's disease
AU1407399A (en) * 1997-11-14 1999-06-07 Eli Lilly And Company Treatment for alzheimer's disease
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EP1062205A2 (en) * 1998-02-25 2000-12-27 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EP1058547B1 (en) * 1998-03-03 2005-11-23 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium 3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
EP1066290A1 (en) 1998-03-31 2001-01-10 Shionogi & Co., Ltd. PYRROLO[1,2-a]PYRAZINE sPLA 2 INHIBITOR
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
CZ302588B6 (cs) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
DZ2770A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
JP2002512222A (ja) * 1998-04-17 2002-04-23 イーライ・リリー・アンド・カンパニー 4−ヒドロキシインドール、インダゾール、及び、カルバゾール化合物の製造方法
US6407261B1 (en) 1998-04-17 2002-06-18 Eli Lilly And Company Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
ID27153A (id) 1998-05-01 2001-03-08 Lilly Co Eli Senyawa inhibitor spla2 untuk mengobati penyakit
IL139203A0 (en) * 1998-05-01 2001-11-25 Lilly Co Eli Spla2 inhibitor ester
EP1085021A4 (en) 1998-05-21 2003-01-08 Shionogi & Co DERIVATIVES OF PYRROLO 1,2-B] PYRIDAZINE, WITH INHIBITOR EFFECT ON SPLA 2?
ATE326963T1 (de) * 1998-08-03 2006-06-15 Lilly Co Eli Indolverbindungen als spla2 inhibitoren
WO2000007591A1 (en) * 1998-08-03 2000-02-17 Eli Lilly And Company INDOLE sPLA2 INHIBITORS
WO2000010568A1 (en) 1998-08-24 2000-03-02 Draheim Susan E Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase a¿2?
US6576654B1 (en) 1998-09-23 2003-06-10 Eli Lilly And Company Method for the treatment of cystic fibrosis
DZ2771A1 (fr) * 1998-10-09 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
DE69931963D1 (de) * 1998-10-14 2006-07-27 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
US20030149000A1 (en) * 1998-11-10 2003-08-07 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds
EP1214041A2 (en) * 1998-12-21 2002-06-19 Eli Lilly And Company Combination therapy for the treatment of sepsis
WO2000037472A2 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company Substituted pirroloindoles
AU2373600A (en) * 1998-12-22 2000-07-12 Eli Lilly And Company Novel spla2 inhibitors
US6380397B1 (en) 1999-04-15 2002-04-30 Eli Lilly And Company Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6274578B1 (en) 1999-04-20 2001-08-14 Eli Lilly And Company sPLA2 inhibitor ester
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
US6703385B1 (en) 1999-07-19 2004-03-09 Shionogi & Co., Ltd. Tricyclic compounds having sPLA2-inhibitory activities
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
CA2379208A1 (en) * 1999-07-19 2001-01-25 Eli Lilly & Company Spla2 inhibitors
US6673781B1 (en) 1999-08-02 2004-01-06 Shionogi & Co., Ltd. Tricyclic compounds having sPLA2-inhibitory activities
WO2001014378A1 (fr) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
WO2001021587A2 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors
US6831095B1 (en) 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
WO2001026653A1 (fr) * 1999-10-15 2001-04-19 Shionogi & Co., Ltd. Inhibiteurs spla2 du type v et/ou du type x
WO2001036420A1 (fr) 1999-11-15 2001-05-25 Shionogi & Co., Ltd. Derives d'aza-indolizine tricyclique ayant un effet inhibiteur sur spla¿2?
WO2001044185A1 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
WO2001044184A1 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Synthesis of indole-containing spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
JP2003519198A (ja) * 2000-01-06 2003-06-17 イーライ・リリー・アンド・カンパニー 炎症性疾患および呼吸器疾患の処置のための併用療法
US20030096854A1 (en) * 2002-06-12 2003-05-22 Ho-Shen Lin Substituted tricyclics
WO2001049662A2 (en) * 2000-01-07 2001-07-12 Eli Lilly And Company Carbazole derivatives as inhibitors of spla2
EP1265607A2 (en) * 2000-03-09 2002-12-18 Eli Lilly And Company METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS
BR0002188A (pt) * 2000-03-30 2001-11-13 Brasil Compressores Sa Processo de formação do pacote de lâminasmetálicas de estator de motor elétrico e pacotede lâminas metálicas
AU2001252922A1 (en) * 2000-04-19 2001-11-07 Eli Lilly And Company Azide cyclization-based synthesis and intermediates for spla2 inhibitors
ES2294003T3 (es) * 2000-06-29 2008-04-01 Anthera Pharmaceuticals, Inc. Remedios contra el cancer.
US20040102442A1 (en) * 2000-06-29 2004-05-27 Kohji Hanasaki Remedies for alzheimer's disease
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
BR0112460A (pt) * 2000-07-14 2003-07-22 Lilly Co Eli Método para tratamento de sépsis
WO2002012249A2 (en) * 2000-08-04 2002-02-14 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
EP1358156B1 (en) * 2000-12-18 2007-02-21 Eli Lilly And Company Benz(g) indoles and their use as spla2 inhibitors
TWI314457B (sv) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
TWI323658B (en) 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
JP2009515837A (ja) * 2005-11-03 2009-04-16 イリプサ, インコーポレイテッド C4−酸性置換基を有するインドール化合物およびホスホリパーゼa2インヒビターとしてのその使用
EP1948602A2 (en) * 2005-11-03 2008-07-30 Ilypsa, Inc. Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors
CA2627043A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
JP2009514883A (ja) * 2005-11-03 2009-04-09 イリプサ, インコーポレイテッド アザインドール化合物およびホスホリパーゼa2インヒビターとしてのその使用
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
WO2009133831A1 (ja) * 2008-04-28 2009-11-05 旭化成ファーマ株式会社 フェニルプロピオン酸誘導体及びその用途
JP2012514652A (ja) * 2009-01-08 2012-06-28 アンセラ・ファーマシューティカルズ・インコーポレイテッド 心血管疾患および脂質異常症を治療するための分泌ホスホリパーゼa2(spla2)インヒビターとナイアシン薬との組成物および方法
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN101838232B (zh) * 2009-07-07 2012-02-22 爱斯医药科技(南京)有限公司 Varespladib的制备方法
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
CN108463221A (zh) * 2015-08-31 2018-08-28 迪亚库雷特公司 吲哚类化合物刺激免疫系统的用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
US2825743A (en) 1955-08-30 1958-03-04 Celanese Corp Catalytic hydrogenation of unsaturated aldehydes and ketones
US3242163A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3259622A (en) * 1962-09-07 1966-07-05 Merck & Co Inc 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
GB1089071A (en) 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
NL287416A (sv) 1964-04-25
US3449363A (en) 1966-12-22 1969-06-10 American Cyanamid Co 3-substituted 4-trifluoromethyl indoles
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
US3691194A (en) * 1970-07-30 1972-09-12 Little Inc A 3-indole-glyoxamides
US3686213A (en) 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
US4012513A (en) * 1971-11-03 1977-03-15 Imperial Chemical Industries Limited Indole derivatives for providing analgesic and anti-inflammatory effects
US4397850A (en) 1981-10-07 1983-08-09 Sandoz, Inc. Isoxazolyl indolamines
US4552876A (en) * 1984-07-09 1985-11-12 Usv Pharmaceutical Corp. Bisbenzoxazines and pharmaceutical use
US4792555A (en) * 1987-03-20 1988-12-20 American Home Products Corporation Phospholipase A2 inhibitors
NZ234883A (en) * 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5192770A (en) * 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
US5334719A (en) * 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
PL180523B1 (pl) 1994-04-01 2001-02-28 Eli Lilly & Co Nowy zwiazek, pochodna 1H-indolo-3-glioksylamidu i srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
IL124613A0 (en) 1995-12-14 1998-12-06 Merck & Co Inc Antagonists of gonadotropin releasing hormone
DE69620241T2 (de) * 1995-12-14 2002-10-02 MERCK & CO., INC. (A NEW JERSEY CORP.) Gonadotropin releasing hormon- antagonisten
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors

Also Published As

Publication number Publication date
NZ270848A (en) 1997-05-26
PE18696A1 (es) 1996-05-30
AU1621795A (en) 1995-10-12
NO951252L (no) 1995-10-02
JPH07285933A (ja) 1995-10-31
RU95104885A (ru) 1997-04-27
EP1081135A3 (en) 2003-11-05
CA2146097C (en) 2000-03-21
FI951553A0 (sv) 1995-03-31
IL113210A0 (en) 1995-06-29
NO304186B1 (no) 1998-11-09
EP2341045A1 (en) 2011-07-06
EP1081135A2 (en) 2001-03-07
BR9501404A (pt) 1996-03-05
AU688458B2 (en) 1998-03-12
ZA952693B (en) 1996-09-30
ES2377223T3 (es) 2012-03-23
HUT72048A (en) 1996-03-28
JP3109974B2 (ja) 2000-11-20
US5919810A (en) 1999-07-06
DE69527322D1 (de) 2002-08-14
DE69527322T2 (de) 2003-02-27
TW383302B (en) 2000-03-01
UA47387C2 (uk) 2002-07-15
PT675110E (pt) 2002-11-29
US5919943A (en) 1999-07-06
CA2146097A1 (en) 1995-10-02
EP1950200B1 (en) 2012-01-11
HU9500957D0 (en) 1995-05-29
ATE540923T1 (de) 2012-01-15
EP0675110A1 (en) 1995-10-04
SI0675110T1 (en) 2002-12-31
NO951252D0 (no) 1995-03-31
MY112897A (en) 2001-10-31
KR100368707B1 (ko) 2003-06-02
US5654326A (en) 1997-08-05
CO4370099A1 (es) 1996-10-07
EP0675110B1 (en) 2002-07-10
PL180523B1 (pl) 2001-02-28
ATE220394T1 (de) 2002-07-15
DK1950200T3 (da) 2012-04-10
US5733923A (en) 1998-03-31
EP1950200A1 (en) 2008-07-30
CZ82295A3 (en) 1995-12-13
MX9501608A (es) 1997-02-28
CN1067054C (zh) 2001-06-13
US6433001B1 (en) 2002-08-13
DK0675110T3 (da) 2002-10-07
EP1197484A2 (en) 2002-04-17
RU2128169C1 (ru) 1999-03-27
PL307951A1 (en) 1995-10-02
FI951553A (sv) 1995-10-02
ES2179088T3 (es) 2003-01-16
US6175021B1 (en) 2001-01-16
FI114793B (sv) 2004-12-31
CN1114310A (zh) 1996-01-03
KR950032117A (ko) 1995-12-20

Similar Documents

Publication Publication Date Title
EP0675110B1 (en) 1H-Indole-3-glyoxylamide sPLA2 inhibitors
EP0772592B1 (en) 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS
RU2162463C2 (ru) Новые 1н-индол-3-ацетамиды как ингибиторы spla2 и фармацевтическая композиция на их основе
EP0620214B1 (en) 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors
US6252084B1 (en) 1H-indole-3-acetamide sPLA2 inhibitors
EP1202963B1 (en) Spla2 inhibitors
US6635670B2 (en) sPLA2 inhibitors
Bach et al. 1H-indole-3-glyoxylamide SPLA 2 inhibitors
Bach et al. 1H-indole-1-functional sPLA 2 inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees